{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T19:56:47Z","timestamp":1791489407467,"version":"4.3.4"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Immunological Methods"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.jim.2019.112688","type":"journal-article","created":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T03:47:00Z","timestamp":1572580020000},"page":"112688","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["A novel approach to assess domain specificity of anti-drug antibodies to moxetumomab pasudotox, an immunotoxin with two functional domains"],"prefix":"10.1016","volume":"477","author":[{"given":"Inna","family":"Vainshtein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorin K.","family":"Roskos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meina","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jim.2019.112688_bb0005","unstructured":"Anon AstraZeneca Pharmaceuticals LP, Wilmington, DE. 2018."},{"issue":"1","key":"10.1016\/j.jim.2019.112688_bb0010","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1002\/cncr.22739","article-title":"Antibody against poly(ethylene glycol) adversely affects PEG-asparaginase therapy in acute lymphoblastic leukemia patients","volume":"110","author":"Armstrong","year":"2007","journal-title":"Cancer"},{"issue":"7","key":"10.1016\/j.jim.2019.112688_bb0015","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1056\/NEJMoa020888","article-title":"Influence of immunogenicity on the long-term efficacy of infliximab in Crohn\u2019s disease","volume":"348","author":"Baert","year":"2003","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.jim.2019.112688_bb0020","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1093\/jnci\/djz035","article-title":"Antibody-drug conjugate-based therapeutics: state of the science","volume":"111","author":"Birrer","year":"2019","journal-title":"J. Natl. Cancer Inst."},{"issue":"4","key":"10.1016\/j.jim.2019.112688_bb0025","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/j.xphs.2016.12.023","article-title":"An \u201cFc-silenced\u201d IgG1 format with extended half-life designed for improved stability","volume":"106","author":"Borrok","year":"2017","journal-title":"J. Pharm. Sci."},{"issue":"4","key":"10.1016\/j.jim.2019.112688_bb0030","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1021\/bc5005747","article-title":"Effect of attachment site on stability of cleavable antibody drug conjugates","volume":"26","author":"Dorywalska","year":"2015","journal-title":"Bioconjug. Chem."},{"issue":"4","key":"10.1016\/j.jim.2019.112688_bb0035","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.jmb.2011.06.031","article-title":"Whole-molecule antibody engineering: generation of a high-affinity anti-IL-6 antibody with extended pharmacokinetics","volume":"411","author":"Finch","year":"2011","journal-title":"J. Mol. Biol."},{"issue":"1","key":"10.1016\/j.jim.2019.112688_bb0040","doi-asserted-by":"crossref","first-page":"R12","DOI":"10.1186\/ar1861","article-title":"Control of hyperuricemia in subjects with refractory gout, and induction of antibody against poly(ethylene glycol) (PEG), in a phase I trial of subcutaneous PEGylated urate oxidase","volume":"8","author":"Ganson","year":"2006","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jim.2019.112688_bb0045","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jim.2014.05.010","article-title":"Recommendations for the characterization of immunogenicity response to multiple domain biotherapeutics","volume":"408","author":"Gorovits","year":"2014","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.jim.2019.112688_bb0050","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.3389\/fimmu.2018.02460","article-title":"CAR-T cells and oncolytic viruses: joining forces to overcome the solid tumor challenge","volume":"9","author":"Guedan","year":"2018","journal-title":"Front. Immunol."},{"issue":"9","key":"10.1016\/j.jim.2019.112688_bb0055","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.4155\/bio.13.10","article-title":"Immunogenicity testing strategy and bioanalytical assays for antibody-drug conjugates","volume":"5","author":"Hoofring","year":"2013","journal-title":"Bioanalysis"},{"issue":"12","key":"10.1016\/j.jim.2019.112688_bb0060","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.2174\/0929867324666170113112759","article-title":"Fc-fusion proteins in therapy: an updated view","volume":"24","author":"Jafari","year":"2017","journal-title":"Curr. Med. Chem."},{"issue":"2","key":"10.1016\/j.jim.2019.112688_bb0065","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1080\/19420862.2018.1556465","article-title":"Antibodies to watch in 2019","volume":"11","author":"Kaplon","year":"2019","journal-title":"MAbs"},{"issue":"7","key":"10.1016\/j.jim.2019.112688_bb0070","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.drudis.2015.02.008","article-title":"Bispecific antibodies","volume":"20","author":"Kontermann","year":"2015","journal-title":"Drug Discov. Today"},{"issue":"20","key":"10.1016\/j.jim.2019.112688_bb0075","doi-asserted-by":"crossref","first-page":"6398","DOI":"10.1158\/1078-0432.CCR-11-0487","article-title":"Antibody fusion proteins: anti-CD22 recombinant immunotoxin moxetumomab pasudotox","volume":"17","author":"Kreitman","year":"2011","journal-title":"Clin. Cancer Res."},{"issue":"8","key":"10.1016\/j.jim.2019.112688_bb0080","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1038\/s41375-018-0210-1","article-title":"Moxetumomab pasudotox in relapsed\/refractory hairy cell leukemia","volume":"32","author":"Kreitman","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.jim.2019.112688_bb0085","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/1298473","article-title":"Immunogenicity of biotherapeutics: causes and association with posttranslational modifications","volume":"2016","author":"Kuriakose","year":"2016","journal-title":"J Immunol Res"},{"key":"10.1016\/j.jim.2019.112688_bb0090","doi-asserted-by":"crossref","first-page":"113","DOI":"10.12688\/f1000research.9970.1","article-title":"Recent advances in (therapeutic protein) drug development","volume":"6","author":"Lagasse","year":"2017","journal-title":"F1000Res"},{"issue":"1","key":"10.1016\/j.jim.2019.112688_bb0095","doi-asserted-by":"crossref","first-page":"5","DOI":"10.2174\/1389201019666180418095526","article-title":"CAR T-cell therapy: a new era in cancer immunotherapy","volume":"19","author":"Miliotou","year":"2018","journal-title":"Curr. Pharm. Biotechnol."},{"issue":"3","key":"10.1016\/j.jim.2019.112688_bb0100","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s40259-016-0174-5","article-title":"Assessing the immunogenicity of biopharmaceuticals","volume":"30","author":"Pineda","year":"2016","journal-title":"BioDrugs"},{"issue":"6","key":"10.1016\/j.jim.2019.112688_bb0105","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1016\/j.jaci.2016.04.058","article-title":"Pre-existing anti-PEG antibodies are associated with severe immediate allergic reactions to pegnivacogin, a PEGylated aptamer","volume":"138","author":"Povsic","year":"2016","journal-title":"J. Allergy Clin. Immunol."},{"issue":"1","key":"10.1016\/j.jim.2019.112688_bb0110","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s10020-018-0051-4","article-title":"Bi-specific and tri-specific antibodies- the next big thing in solid tumor therapeutics","volume":"24","author":"Runcie","year":"2018","journal-title":"Mol. Med."},{"issue":"2","key":"10.1016\/j.jim.2019.112688_bb0115","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1093\/rheumatology\/kev277","article-title":"Immunogenicity of biologic agents in rheumatoid arthritis patients: lessons for clinical practice","volume":"55","author":"Schaeverbeke","year":"2016","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"10.1016\/j.jim.2019.112688_bb0120","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/nrd818","article-title":"Bioequivalence and the immunogenicity of biopharmaceuticals","volume":"1","author":"Schellekens","year":"2002","journal-title":"Nat. Rev. Drug Discov."},{"issue":"10","key":"10.1016\/j.jim.2019.112688_bb0125","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1093\/protein\/gzw040","article-title":"Novel human IgG1 and IgG4 fc-engineered antibodies with completely abolished immune effector functions","volume":"29","author":"Schlothauer","year":"2016","journal-title":"Protein Eng Des Sel"},{"key":"10.1016\/j.jim.2019.112688_bb0130","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.jim.2016.05.007","article-title":"An immunoinhibition approach to overcome the impact of pre-existing antibodies on cut point establishment for immunogenicity assessment of moxetumomab pasudotox","volume":"435","author":"Schneider","year":"2016","journal-title":"J. Immunol. Methods"},{"issue":"5","key":"10.1016\/j.jim.2019.112688_bb0135","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/j.jpba.2008.09.020","article-title":"Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products","volume":"48","author":"Shankar","year":"2008","journal-title":"J. Pharm. Biomed. Anal."},{"issue":"4","key":"10.1016\/j.jim.2019.112688_bb0140","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1208\/s12248-014-9599-2","article-title":"Assessment and reporting of the clinical immunogenicity of therapeutic proteins and peptides-harmonized terminology and tactical recommendations","volume":"16","author":"Shankar","year":"2014","journal-title":"AAPS J."},{"issue":"9","key":"10.1016\/j.jim.2019.112688_bb0145","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1158\/2326-6066.CIR-14-0191","article-title":"Identification and characterization of MEDI4736, an antagonistic anti-PD-L1 monoclonal antibody","volume":"3","author":"Stewart","year":"2015","journal-title":"Cancer Immunol Res"},{"issue":"4","key":"10.1016\/j.jim.2019.112688_bb0150","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s40259-017-0231-8","article-title":"Immunogenicity of biologics in chronic inflammatory diseases: a systematic review","volume":"31","author":"Strand","year":"2017","journal-title":"BioDrugs"},{"key":"10.1016\/j.jim.2019.112688_bb0155","series-title":"Immunogenicity Testing of Therapeutic Protein Products \u2014Developing and Validating Assays for Anti-Drug Antibody Detection Guidance for Industry","author":"U.S. Department of Health and Human Services","year":"2019"},{"key":"10.1016\/j.jim.2019.112688_bb0160","doi-asserted-by":"crossref","unstructured":"Vezina, H.E., et al., Antibody-Drug Conjugates as Cancer Therapeutics: Past, Present, and Future. J Clin Pharmacol, 2017. 57 Suppl 10: p. S11-S25.","DOI":"10.1002\/jcph.981"},{"issue":"5","key":"10.1016\/j.jim.2019.112688_bb0165","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.biologicals.2015.06.004","article-title":"Immunogenicity assessment of biotherapeutic products: an overview of assays and their utility","volume":"43","author":"Wadhwa","year":"2015","journal-title":"Biologicals"},{"issue":"Pt B","key":"10.1016\/j.jim.2019.112688_bb0170","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.jconrel.2016.06.040","article-title":"Anti-PEG antibodies in the clinic: current issues and beyond PEGylation","volume":"244","author":"Zhang","year":"2016","journal-title":"J. Control. Release"}],"container-title":["Journal of Immunological Methods"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002217591930208X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002217591930208X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T16:38:36Z","timestamp":1758299916000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S002217591930208X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":34,"alternative-id":["S002217591930208X"],"URL":"https:\/\/doi.org\/10.1016\/j.jim.2019.112688","relation":{},"ISSN":["0022-1759"],"issn-type":[{"value":"0022-1759","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A novel approach to assess domain specificity of anti-drug antibodies to moxetumomab pasudotox, an immunotoxin with two functional domains","name":"articletitle","label":"Article Title"},{"value":"Journal of Immunological Methods","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jim.2019.112688","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"112688"}}